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tional and structural multi modality imaging tool that can be utilized to detect vulnerable and ath-
erosclerotic plaques. In this study we observe the prevalence of active and calciﬁed plaques in
selected arteries during whole-body 18F-FDG PET-CT and correlate the ﬁndings with risk factors
in developing coronary artery disease. There was a signiﬁcant relationship between patients with
high body mass index and vulnerable plaques. We concluded that 18F-FDG PET-CT can be utilized
in detecting focal high FDG uptake within vascular plaque in early recognition of high risk patients
having vascular accidents.
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.0021. Introduction
Ischaemic heart disease and cerebrovascular accidents are the
leading cause of death in many countries in the world.1 Despite
major advances in the prevention and treatment of vascular dis-
eases, they remain to be the worldwide leading cause of morbid-
ity, mortality and sudden death. Vascular events have been
thought to be caused by sudden rupture of a vascular plaque,
resulting in either thrombosis at the site of rupture or distal embo-
lization into smaller arteries resulting in reduced blood supply or
total occlusion.2Histologically, cross sectional atheromatous pla-
que reveals layers of fatty deposits in the intima of an artery. This
abnormal accumulation of fats alters the inner lining of arterial
lumen leading to constriction and over time, obstruction to blood
ﬂow. Atheromatous plaque can be inﬂamed, detached from itslexandria University Faculty of Medicine.
Table 1 Descriptive patient characteristics (n= 30).
Characteristic N (n= 30) Percentage (%)
Age group (years)
<30 1 3.3
31–40 4 13.3
41–50 9 30
51–60 6 20
>60 10 33.30
BMI (kg/m2)
15.00–18.49 (underweight) 2 6.67
18.50–24.99 (normal) 16 53.3
25.00–29.99 (overweight) 9 30
30.00–34.99 (obese) 3 10
Gender
Male 19 63.3
Female 11 36.7
Ethnicity
Chinese 13 41.9
Malay 12 38.7
Indian 5 16.1
Risk factors
Smoking status
Smoker 10 32.3
Non-smoker 20 64.5
Hypertension 11 35.5
Diabetes mellitus 4 13.3
Hyperlipidemia 7 22.6
Family history
Heart disease 6 19.4
Hypertension 12 38.7
Diabetes mellitus 9 29
330 S. Shaharuddin et al.origin and thrombosed smaller arteries thus deﬁned as ‘vulnera-
ble plagues’. There has been a strong association of vulnerable
plaques with sedentary and stressful lifestyle, smokers and those
with high risks of vascular events.3 Various imaging modalities
have been used in the clinical investigation of vascular plaque
including ultrasonography, Magnetic Resonance Imaging
(MRI) and Multi Detector Computed Tomography (MDCT).
However, the ability of these modalities in identifying vulnerable
plaques is very limited. On the other hand, Optical Coherence
Tomography (OCT) and Intra Vascular Ultra Sound (IVUS)
are more invasive. In this study, we investigated the prevalence
of inﬂamed vascular plaque in selected medium and large size
arteries and correlate the ﬁndings in our patients with risk factors
in developing coronary artery disease using 18-ﬂuorine ﬂuorode-
oxyglucose as a marker in non invasive integrated dual imaging
modality PET-CT.
2. Materials and methods
This study was conducted with the approval of local ethics
committee.
2.1. Patient selection
Thirty oncology patients referred for staging at diagnosis were
included in this retrospective study. All patients underwent
whole body FDG PET-CT study between April 2010 and Sep-
tember 2011 at the centre for Diagnostic Nuclear Imaging of
Universiti Putra Malaysia. We include the data from 30 adult
patients in our analysis. Past and present clinical history of
high risk factors in developing cardiovascular events was ob-
tained from all patients via prospective telephone interview.
All PET-CT imaging studies were performed following stan-
dard protocol. All patients were required to be fasted for at
least 6 h before the study. In the morning of the study, fasting
blood glucose level was measured followed by intravenous tra-
cer injection of 8–10 mCi of 18F-FDG. The patients were put
to rest in a conﬁnement room with an uptake time of approx-
imately 60 min before imaging. Patients’ characteristics are
tabulated (Table 1).
2.2. Imaging technique
Studies were standardized using a dedicated integrated PET-
CT system (Siemens Truepoint Biograph – TrueV). This
device comprises of a dedicated PET scanner with Optimum
Performance in 3-D Imaging with Lutetium Oxyorthosilicate
(LSO) scintillator crystal technology, which provides fast coin-
cidence timing, efﬁcient rejection of random events, high light
output and high count rates. The camera widens the axial ﬁeld
of view by 33%, which increases count rate performance by
70%, better than older scan generation in which shorter acqui-
sition time can be performed. The system is incorporated with
a multislice CT scanner with capability for 64 slice CT and
high spatial resolution. In view of the higher sensitivity of this
system, the acquisition time for PET was 2 min per table
position. CT data were re-sized from a 512 · 512 matrix to a
128 · 128 matrix to match the PET data to allow image fusion
and generation of CT transmission maps. PET images
were reconstructed using ordered-subsets expected maximiza-
tion (OSEM) with segmented measurement of attenuationcorrection using CT data with four iterations and 16 subsets.
Post reconstruction smoothing of images was performed using
a 5 mm FWHMGaussian ﬁlter. PET and CT images were then
fused, creating an image of distributed 18F-FDG overlying the
corresponding anatomy and physiology generated using a
dedicated workstation.
2.3. Image analysis
The images were reviewed systematically. The maximum
intensity projection (MIP) was ﬁrst analysed for adequacy
of FDG uptake intensity. The distribution was threshold with
the highest activity within the bladder and or renal excretion.
Several sites were selected including bilateral carotids, ascend-
ing, arch and descending aorta, the abdominal aorta at supra
and infra renal locations and the iliac arteries. Reconstructed
images were reviewed in trans axial, coronal and sagittal
planes. The images were reviewed using CT looking for mor-
phological changes in the wall of the arteries and PET look-
ing for focal increase in 18F-FDG uptake. Focal changes
detectable in any of the modalities were analysed in detail.
In axial images, two lines in x and y-axis, perpendicular to
each other were drawn crossing the central lumen of the ar-
tery. On co registered PET-CT slices, 1 cm simple circular re-
gions of interest (ROIs) were placed so as to cover the four
sites that had been chosen as control that is divided into four
quadrants (2 o’clock, 4 o’clock, 8 o’clock and 10 o’clock) in
Figure 2 Control sites demonstrated in grey scale. Region of
interest drawn at three sites (2 o’clock, 4 o’clock and 8 o’clock)
within similar level of plaque localization.
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rial walls and lumen (Fig. 1). The sites chosen are used to dif-
ferentiate between ‘lesion’ and ‘control’ areas (Fig. 2). On
each slice, the mean and maximum standardized uptake val-
ues (SUV) of 18F-FDG derived from the ROI were calculated
as the mean and maximum pixel activity that is used to detect
inﬂamed vascular wall (Fig. 3). While CT images were ana-
lysed by observing corresponding calciﬁcations and calculat-
ing the CT value in Hounsﬁeld unit (HU). The relationship
between plaque composition by means of CT value correlat-
ing calcium content and raised metabolic activity by means of
maximum Standardized Uptake Value (SUVmax) at various
sites of arterial walls were obtained and tabulated (Table 3).
Computer generated SUVmax was obtained using gross body
weight. Comparing the mean physiological uptake within the
liver and blood pool, the value between second and third
quartile is consider as signiﬁcant activity ranging between
1.7 and 1.9.
2.4. Statistic analysis
Univariate descriptive analysis was carried out to the presence
of vascular wall activity (SUV) and calciﬁed artery (HU) in the
socio-demographic characteristics (including gender, age
group, and body mass index (BMI), ethnic group, smoking sta-
tus, hypertension, diabetes mellitus and relevant family his-
tory. Categorical data described using frequency and
percentages. Numerical data described using means and stan-
dard deviation depending on distribution of respective vari-
ables (Table 2). Risk factors (age, BMI, ethnic, gender,
smoking status, hypertension, diabetes mellitus, hyperlipid-
emia and relevant family history) were correlated with SUV
using either independent t-test or ANOVA. The variable of
HU was not normally distributed (left skewed). Therefore,
the logarithmic transformations were performed for HUFigure 1 A foci of calciﬁcation within vascular wall with Cbefore data analyses. Pearson’s-r were used to test correlation
between calciﬁed artery (in HU) and metabolic activity (ex-
pressed in SUVmax) in inﬂamed vascular wall. All data anal-
yses were performed using statistical Package for Sciences
(SPSS) version 19 where p-values below 0.05 are considered
as a signiﬁcant ﬁnding.T value of 550 HU (hard plaque) at 10 o’clock position.
Figure 3 Inﬂamed vascular plaque at 10 o’clock position with CT value of 43 (mean HU) and metabolic activity of SUVmax: 3.34.
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Functional imaging modality Positron Emission Tomography
(PET) using Fluorodeoxyglucose (FDG) as biotracer is known
to improve the accuracy of many oncology diagnoses. Being an
analogue of glucose, FDG is phosphorylated by glucose-6-
phosphate dehydrogenase during glycolysis process at a rate
directly related to tumour aggressiveness. This principle of
FDG metabolism in malignant tumour is applicable in imag-
ing inﬂammatory conditions and infection albeit lower inten-
sity of FDG uptake is expected comparing to malignancy
during PET imaging study like in the case of vulnerable plaque
imaging. The combination of PET and CT in a single instru-
ment enables the exact anatomical assignment of focally in-
creased 18F-FDG uptake to a speciﬁc region which also
allows the detection and quantiﬁcation of vascular calciﬁca-
tions.4 Early localization of vulnerable plaques by means of
functional metabolic imaging using FDG can facilitate early
interventions preventing possible near future vascular events.5
4. Results
4.1. Patient characteristics
The mean age of patients in our study is 51.67 ± 16.5 year
with male predominant (63.3%). Most of our patients are Chi-
nese ethnic followed by Malays and Indian with 3:2:1 ratio.
One third of our patients fall under overweight category
(BMI 29.99 kg/m2) while the majority are within normal
weight range (53.3%). Majority of our patients are within high
risk group (73.3%) where more than half have multiple risks in
developing cardiovascular disease (53.3%) in comparison to
single risk group (20%). One third are smokers while the
remaining two thirds are non smokers. Of the 30 patients, none
of them had any past history of cardiac events, two died from
their oncology disease.4.2. Relationship between SUVmax and HUmax with
cardiovascular risk factors
There is a signiﬁcant relationship between calciﬁed plaque area
(HU> 150) and risk of cardiovascular disease which includes
male gender, older age group, high body mass index, hyperten-
sion, hyperlipidemia and family history of hypertension and dia-
betes mellitus. In addition, we also found a direct correlation
between high SUVBW and body mass index of patients. We
observed majority of Chinese having the highest prevalence of
calciﬁed plaque while Indians having the highest uptake of
18F-FDG. Overall, the uptake of FDG in vascular wall is found
to be higher in male gender, obese, younger age group, smoker
and history of diabetes mellitus and heart disease.
Plaque characterization is tabulated in Table 3. Majority of
hard plaque formation is evident within the wall of aortic
arch (674.5 ± 399.3 HU), right (593.71 ± 381.4 HU) and left
(551.1 ± 384.25 HU) iliac arteries with CT value >150 HU.
The highest range of SUVmax found in association with
plaque formation of vascular wall falls within the second and
third quartile ranging between 1.67 ± 0.30 and 1.99 ± 0.11.
4.3. Relationship between SUVmax and HUmax
The correlation between calciﬁed plaque and FDG uptake is
signiﬁcant (p< 0.05) with moderate Pearson correlation of
0.6 at 95% conﬁdent interval (95% CI). The mean CT value
is 2.23 ± 0.15 (log10 HU) and mean SUVmax is 1.87 ± 0.50
in the majority of studied lesions. The correlation between cal-
ciﬁed plaque (log10HU) and FDG uptake (SUVmax) is signif-
icant (p <0.05) with moderate correlation strength (r = 0.6).
The mean CT value is 2.23 ± 0.15 (log10 HU) and mean SUV-
max is 1.87 ± 0.50 in the majority of studied lesions. Guild-
ford’s rule of thumb for interpreting degree, size, strength or
magnitude of relationship is divided into ﬁve strengths which
are as follows:
Table 2 The relationship between SUVmax and HUmax, with patient demographics and risk factors by using an independent t-test
for < 2 variables and ANOVA for > 2 variables.
Variables (Risk factors) n Vulnerable plaque (SUVmax) Calciﬁed plaque area
Mean ± S.D p-value Mean ± S.D p-value
Gender
Male 19 1.86 ± 0.41 187.9 ± 137.6
Female 11 1.79 ± 0.37 0.486 184.9 ± 116.8 0.014
Age
<30 1 – 144.2 ± 11.67
31–40 4 2.17 ± 0.45 155.9 ± 46.50
41–50 9 1.66 ± 0.32 0.073 171.9 ± 94.52 0.0001
51–60 6 1.87 ± 0.49 178.9 ± 81.54
>60 10 1.85 ± 0.37 221.5 ± 190.1
BMI (kg/m2)
Underweight 2 1.05 144.9 ± 46.9
Normal 16 1.77 ± 0.38 178 ± 107.6
Overweight 9 1.87 ± 0.38 0.031 212.6 ± 173.7 0.0001
Obese 3 2.17 ± 0 .45 169.7 ± 60.6
Ethnic
Chinese 13 1.77 ± 0.32 207.9 ± 172.4
Malay 12 1.88 ± 0.38 0.126 173.4 ± 82.54 0.0001
Indian 5 2.00 ± 0 .61 170.8 ± 106.0
Smoking status
Smoker 10 1.90 ± 0.39 0.176 180.7 ± 113.9 0.944
Non-smoker 20 1.79 ± 0.41 190.3 ± 138.9 Non-smoker
Hypertension
Yes 11 1.78 ± 0.33 0.089 215.2 ± 180.6 0.0001
No 19 1.96 ± 0.51 167.8 ± 75.47 No
Diabetes mellitus
Yes 4 1.91 ± 0.37 0.296 198.1 ± 149.9 0.83
No 26 1.81 ± 0.41 184.5 ± 126.0 No
Hyperlipidemia
Yes 7 1.80 ± 0.32 0.524 205.4 ± 167.8 0.0001
No 23 1.86 ± 0.44 180 ± 113.1
Family history of heart disease
Yes 6 1.96 ± 0.36 0.103 194.3 ± 101.8 0.566
No 24 1.80 ± 0.40 184.9 ± 136.5 No
Hypertension
Yes 12 1.83 ± 0.35 0.81 195.8 ± 163.7 0.0001
No 18 1.85 ± 0.44 180.8 ± 101.9 No
Diabetes mellitus
Yes 9 1.86 ± 0.386 0.554 208.3 ± 180.5 0.0001
No 21 1.81 ± 0.416 176.0 ± 94.24 No
Signiﬁcant at p value <0.05.
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r= 0.3–0.49 Low relationship.
r= 0.5–0.69 Moderate or marked relationship.
r= 0.7–0.89 Strong relationship.
r= 0.9–1.0 Very strong relationship.
Our patients demonstrate no co-relationship between calci-
ﬁed plaque and metabolic activity where at 95% conﬁdent
interval, the R square value is 0.004 Fig. 4.
5. Discussion
Our study found that 18F-FDG can be used to detect vulnera-
ble plaques. The maximum SUVBW intensity greater than 1.8can be utilized as the cut-off value in stratifying patients at
our centre having risk of thrombo-emboli complications.
In recent years, atherosclerotic disease has become a recog-
nized contributor towards worldwide causes of death from car-
diovascular and stroke diseases.6–13
The mean SUVmax of FDG uptake within vascular plaque
in our study within the majority of studied lesions is
1.87 ± 0.50. This value falls between the second and third
quartile ranging between 1.67 ± 0.30 and 1.99 ± 0.11. In
our set-up this value is above the average value of physiologi-
cal FDG uptake within the liver, spleen and background activ-
ity. Considering the standardized protocol in performing
whole body PET-CT study at our centre including the PET-
CT system, uptake time and imaging protocol, we suggest this
Table 3 The relationship of plaque area (HUmax) and risk factors in developing vulnerable plaque by using independent t test for
variable <2 group and ANOVA test for variable >2 group.
Variable (Risk factor) N (n: 30) Mean ± S.D (plaque area) P value (plaque area)
Gender
Male 19 187.9 ± 137.6
Female 11 184.9 ± 116.8 0.014
Age
<30 1 144.2 ± 11.67
31–40 4 155.9 ± 46.50
41–50 9 171.9 ± 94.52 0.0001
51–60 6 178.9 ± 81.54
>60 10 221.5 ± 190.1
BMI (kg/m2)
15.00–18.49 (underweight) 2 144.9 ± 46.9
18.50–24.99 (normal) 16 178 ± 107.6
25.00–29.99 (overweight) 9 212.6 ± 173.7 0.0001
30.00–34.99 (obese) 3 169.7 ± 60.6
Ethnicity
Chinese 13 207.9 ± 172.4
Malay 12 173.4 ± 82.54 0.0001
Indian 5 170.8 ± 106.0
Smoking status
Smoker 10 180.7 ± 113.9 0.944
Non-smoker 20 190.3 ± 138.9
Hypertension
Yes 11 215.2 ± 180.6 0.0001
No 19 167.8 ± 75.47
Diabetes mellitus
Yes 4 198.1 ± 149.9 0.83
No 26 184.5 ± 126.0
Hyperlipidemia
Yes 7 205.4 ± 167.8 0.0001
No 23 180 ± 113.1
Family history of heart disease
Yes 6 194.3 ± 101.8 0.566
No 24 184.9 ± 136.5
Hypertension
Yes 12 195.8 ± 163.7 0.0001
No 18 180.8 ± 101.9
Diabetes mellitus
Yes 9 208.3 ± 180.5 0.0001
No 21 176.0 ± 94.24
334 S. Shaharuddin et al.value as our reference point for future vulnerable plaque imag-
ing studies, thus patients who demonstrate high 18F-FDG up-
take at imaging may beneﬁt further investigation screening for
risk of cardiovascular disease.
In the study conducted by Vallabojosula et al.14 they found
that the site of aortic FDG uptake correlated well with the site
of calciﬁcation. Based on the pathology of calciﬁed and non
calciﬁed atheromas, it is not surprising that there was little
overlap between the inﬂammatory and calciﬁcation: Correla-
tion between sites of aortic calciﬁcation and foci of FDG up-
take was observed in 7% of patients in one series and in less
than 2% of patients in other series. While Rudd et al.15
recently demonstrated that 18F-FDG uptake was higher in
symptomatic lesion. These observations strongly suggest that
18F-FDG-PET is capable of imaging quantifying plaqueinﬂammation.16–18 Our study found a linear relationship be-
tween calciﬁed atheromatous plaque and high FDG uptake.
In addition, we found high FDG uptake within atheromatous
plaques in high risk group of patients including male gender,
obese, smoker and those with history of diabetes mellitus
and past coronary artery disease. This group of patients also
demonstrate a signiﬁcant high incidence of calciﬁed plaque for-
mation (p= 0.001).
In this study, we highlight the potential of PET-CT, a non
invasive modality in imaging vulnerable and thrombotic pla-
ques using 18F-FDG as marker in high risk groups. 18F
FDG PET-CT was serially performed to investigate whether
there is correlation between vascular 18F-FDG uptake and risk
factor to develop atherosclerosis. The increased 18F-FDG up-
take and calciﬁed vascular wall were most strongly correlated
Figure 4 Scatter plot correlating the relationship of SUVmax
and CT value in log transformed HU (log10).
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found signiﬁcant correlations between BMI and male gen-
der16,17which is in agreement with our study. A few potential
limitations may impair the data analysis of this study. More-
over, most of the FDG uptake sites were not accompanied
by calciﬁcation, each FDG sites were separated from the near-
est calciﬁcation site which may have been caused by inaccurate
integration of PET and CT images due to movement or respi-
ratory motion from the patient 19–21. Besides that, the subject
of the study is limited. Current technology hampers PET cam-
era ability to detect metabolic activity smaller than the cam-
era’s resolution.22–25 In our setting the limitation is 4 mm
dimension. In this observatory study, there are no methods
to validate the FDG uptake of vascular plaques. Other factors
which may induce 18F-FDG uptake should also be considered.
Validation is required to established the relationship between
high 18F-FDG vascular plague activity and vulnerability for
vascular accidents. Its co-relationship with plasma concentra-
tion of established inﬂammatory parameters and endarterec-
tomy ﬁndings require further investigations. The hypothesis
that some foci of increased vascular-wall 18F-FDG uptake
may correspond to early atherosclerosis and may indicate the
presence of a ‘vulnerable’ plaque needs to be further tested
by prospective studies and also continue following-up patients
to ﬁnd the outcome events and survival analysis, so that 18F-
FDG PET-CT may be the tool for early detection of patients
at increased risk of future cardiovascular events and for assess-
ment of early therapies for vascular-wall lesions.
6. Conclusion
There is a role for 18F-FDG PET-CT as a non invasive tool in
detecting vulnerable plaques. This combined imaging modality
can stratify high risk patient in developing thrombo-embolic
vascular diseases. Thus early clinical intervention can be insti-
tuted to prevent cardiovascular or cerebro-vascular events.Acknowledgment
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